Edition:
United States

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

16.49USD
4:00pm EDT
Change (% chg)

$0.14 (+0.83%)
Prev Close
$16.35
Open
$16.29
Day's High
$16.50
Day's Low
$16.05
Volume
115,047
Avg. Vol
366,801
52-wk High
$17.69
52-wk Low
$1.17

Latest Key Developments (Source: Significant Developments)

Endocyte Announces Closing Of Public Offering Of Common Stock
Friday, 2 Mar 2018 04:01pm EST 

March 2 (Reuters) - Endocyte Inc ::ENDOCYTE ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK.  Full Article

Endocyte Announces Pricing Of Public Offering Of Common Stock
Wednesday, 28 Feb 2018 09:17am EST 

Feb 28 (Reuters) - Endocyte Inc ::ENDOCYTE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 17.9 MILLION COMMON SHARES PRICED AT $4.20PER SHARE.  Full Article

Endocyte Announces Proposed Public Offering Of Common Stock
Tuesday, 27 Feb 2018 08:01pm EST 

Feb 27 (Reuters) - Endocyte Inc ::ENDOCYTE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.‍INTENDS TO OFFER AND SELL SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN REGISTERED PUBLIC OFFERING​.  Full Article

Endocyte And ITM Announce Supply Agreement
Monday, 26 Feb 2018 08:00am EST 

Feb 26 (Reuters) - Endocyte Inc ::ENDOCYTE AND ITM ANNOUNCE SUPPLY AGREEMENT FOR NO-CARRIER-ADDED LUTETIUM FOR THE PHASE 3 VISION TRIAL.ENDOCYTE INC - UNDER SUPPLY AGREEMENT, ITM TO SUPPLY TO CO, MEDICAL RADIOISOTOPE NO-CARRIER-ADDED LUTETIUM, ENDOLUCINBETA.ENDOCYTE INC - PHASE 3 VISION TRIAL EXPECTED TO BE INITIATED BY ENDOCYTE IN Q2 OF 2018.  Full Article

Endocyte Announces Phase 3 Vision Trial,Provides Update On Corporate Strategy And Reports Q4 And 2017 Financial Results
Monday, 26 Feb 2018 08:00am EST 

Feb 26 (Reuters) - Endocyte Inc ::ENDOCYTE ANNOUNCES PHASE 3 VISION TRIAL AND PROVIDES UPDATE ON CORPORATE STRATEGY AND REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.18.ANNOUNCED AGREEMENT FOR CLINICAL SUPPLY OF NO-CARRIER-ADDED LUTETIUM WITH ITM.CAR T-CELL THERAPY EXPECTED TO BEGIN CLINICAL DEVELOPMENT IN Q4 OF 2018.‍ ENROLLMENT OF VISION TRIAL IS EXPECTED TO BEGIN IN Q2 OF 2018 AND IS EXPECTED TO BE COMPLETED IN 18-24 MONTHS​.CASH, CASH EQUIVALENTS & INVESTMENTS WERE $97.5 MILLION AT DEC. 31, 2017, VERSUS $103.1 MILLION AT SEPT. 30, 2017.‍ FIRST INTERIM ASSESSMENT OF OS FOR VISION TRIAL COULD OCCUR AS EARLY AS SECOND HALF OF 2019​.ANTICIPATES ITS CASH, CASH EQUIVALENTS AND INVESTMENTS BALANCE AT END OF 2018 TO EXCEED $50 MILLION.HAS SUFFICIENT CASH TO FUND ITS ACTIVITIES INTO SECOND HALF OF 2019 THROUGH MANY IMPORTANT MILESTONES.  Full Article

‍Partner Fund Management LP reports a 6.6 pct passive stake in Endocyte as of Nov 6
Thursday, 16 Nov 2017 04:52pm EST 

Nov 16 (Reuters) - Endocyte Inc :‍Partner Fund Management LP reports a 6.6 percent passive stake in Endocyte Inc as of November 6 - SEC Filing​.  Full Article

Endocyte Q3 loss per share $0.55
Monday, 6 Nov 2017 04:01pm EST 

Nov 6 (Reuters) - Endocyte Inc :Endocyte reports third quarter financial results.Q3 loss per share $0.55.  Full Article

Endocyte Inc files for mixed shelf of upto $150 million
Thursday, 12 Oct 2017 04:40pm EDT 

Oct 12 (Reuters) - Endocyte Inc ::Endocyte Inc files for mixed shelf of upto $150 million .Endocyte Inc says in addition, selling stockholders may offer and sell, up to 5.3 million shares of co's common stock‍​.  Full Article

Peter Dodwell reports 7.1 pct passive stake in Endocyte Inc
Thursday, 12 Oct 2017 04:28pm EDT 

Oct 12 (Reuters) - Endocyte Inc :Peter Dodwell reports 7.1 percent passive stake in Endocyte Inc ‍​as of September 29 - SEC filing.  Full Article

Endocyte announces worldwide license of its radioligand therapy
Monday, 2 Oct 2017 07:30am EDT 

Oct 2 (Reuters) - Endocyte Inc ::Endocyte announces exclusive worldwide license of phase 3 ready PSMA-targeted radioligand therapy for development in prostate cancer.Says under the terms of agreement, co has exclusive worldwide rights to developand commercialize PSMA-617.Announced the completion of a worldwide, exclusive license of PSMA-617from ABX GmbH.Says under the terms of agreement, Endocyte has made an upfront payment of $12 million to ABX.  Full Article

BRIEF-Endocyte Reports Q1 Loss Per Share $0.16

* Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S